Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 329

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 329
---
 appearing elsewhere in this proxy statement/prospectus.

### Overview
Iris is a blank check company incorporated on November 5, 2020 as a Delaware corporation and formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. On November 30, 2022, Iris executed a Business Combination Agreement with Liminatus Pharma, LLC. Iris intends to effectuate the Business Combination using cash from the proceeds of its initial public offering and the private placement of the private placement warrants, the proceeds of the sale of its shares in connection with its Business Combination (pursuant to forward purchase agreements or backstop agreements Iris may enter into following the consummation of its initial public offering or otherwise), shares issued to the owners of the target, debt issued to bank or other lenders or the owners of the target, or a combination of the foregoing. The registration statement for Iris’s initial public offering was declared effective by the SEC on March 4, 2021. On March 9, 2021, Iris consummated the initial public offering of 27,600,000 Units at a price of $10.00 per Unit, for total gross proceeds of $276,000,000. Each Unit consists of one share of Iris Class A Common Stock, $0.0001 par value, and one-fourth of one redeemable warrant entitling its holder to purchase one share of common stock at a price of $11.50 per share.

Simultaneously with the closing of the initial public offering pursuant to warrant purchase agreements, Iris completed the private sale of an aggregate of 5,013,333 private placement warrants to the Sponsor and Cantor Fitzgerald & Co. at a purchase price of $1.50 per private placement warrant. The sale of the private placement warrants generated gross proceeds to Iris of $7,520,000.

On June 1, 2022, Tribe Capital Markets LLC (“Tribe Capital”) withdrew as a member of the Sponsor. In connection with the withdrawal of Tribe Capital as a member of the Sponsor: (1) on July 26, 2022, the following actions occurred: (i) Arjun Sethi resigned in his capacity as Chairman and Chief Executive Officer, (ii) Henry Ward resigned from his role as an independent director, (iii) Omar Chohan resigned from his role as Chief Financial Officer of Iris, and (iv) Ted Maidenberg resigned from his role